AGIO - Agios Pharm

AGIO - Agios Pharm

https://www.agios.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Agios Pharmaceuticals ( NASDAQ:AGIO )

Benzinga • 1 week, 4 days ago

FDA extends Pyrukynd supplemental marketing application decision date to December 7, 2025. REMS submission to address liver injury risk triggered a delay. September's volatility catalysts are coming. Find out how to trade new inflation reports and fed signals here → On Thursday, the U.S.

Agios Pharmaceuticals ( AGIO ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month, 2 weeks ago • score: 0.10

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET - Agios Pharmaceuticals ( NASDAQ:AGIO )

Benzinga • 2 months ago • score: -0.10

CAMBRIDGE, Mass., July 14, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in cellular metabolism and pyruvate kinase ( PK ) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 31, ...

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

GlobeNewswire • 2 months ago

Agios Pharmaceuticals announced it will host a conference call and live webcast on Thursday, July 31, 2025, at 8:00 a.m. ET to report its 2Q results ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.

52W High

$62.58

52W Low

$23.41

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.87

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

3.19

Forward P/E (<15 better)

2.47

EV/EBITDA (<8 favorable)

-2.33

EV/Revenue (<3 favorable)

29.41

P/S (TTM) (<3 favorable)

51.19

P/B (<3 favorable)

1.53

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.68%

Institutions (25–75% balanced)

112.91%

Shares Outstanding

58,102,000

Float

51,348,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

40,875,000

Gross Profit (TTM)

-283,903,008

EPS (TTM)

11.29

Profit Margin (>10% good)

15.90%

Operating Margin (TTM) (higher better)

-10.20%

ROE (TTM) (>15% strong)

0.64%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.45

Momentum

Bearish momentum

Value

-0.2880

Previous

-0.2993

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025